ViAqua Therapeutics has successfully secured a significant investment of USD 8.25 million, led by S2G Ventures, aimed at expanding its RNA-based solutions in aquaculture. The move comes as the aquaculture industry grapples with disease management, causing over USD 8.5 billion in economic impact for the shrimp sector alone, according to Kontali.

Shrimp, lacking adaptive immune systems, face heightened susceptibility to diseases like the White Spot Virus (WSSV), resulting in an annual loss of approximately USD 3 billion and a 15% reduction in global shrimp production. ViAqua’s innovative solution involves a biotechnology-based oral delivery platform for targeted administration of RNA-based solutions, initially focusing on enhancing shrimp resistance to viral infections like WSSV.

ViAqua’s first product, a feed supplement produced through commercial processes, aims to stabilize production for farmers, offering increased yield without raising disease risk. The company has partnered with Skretting, a Nutreco company, for joint development and marketing, marking a significant step towards bringing the product to market.

While ViAqua concentrates on shrimp production, the delivery technology holds promise for broader applications in aquaculture and beyond. CEO Shai Ufaz stressed the significance of oral delivery, citing its ability to reduce operational costs and enhance disease management outcomes. Rabo Ventures’ Investment Director, Shishir Sinha, expressed excitement about ViAqua’s technology, recognizing its potential to make a meaningful impact on the lives of smallholder farmers, who make up 80% of the supply chain.